Systematic Reviews (Jun 2024)

Biomarkers for personalised prevention of chronic diseases: a common protocol for three rapid scoping reviews

  • E Plans-Beriso,
  • C Babb-de-Villiers,
  • D Petrova,
  • C Barahona-López,
  • P Diez-Echave,
  • O R Hernández,
  • N F Fernández-Martínez,
  • H Turner,
  • E García-Ovejero,
  • O Craciun,
  • P Fernández-Navarro,
  • N Fernández-Larrea,
  • E García-Esquinas,
  • I Kuhn,
  • V Jiménez-Planet,
  • V Moreno,
  • F Rodríguez-Artalejo,
  • M J Sánchez,
  • M Pollan-Santamaria,
  • L Blackburn,
  • M Kroese,
  • B Pérez-Gómez

DOI
https://doi.org/10.1186/s13643-024-02554-9
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Introduction Personalised prevention aims to delay or avoid disease occurrence, progression, and recurrence of disease through the adoption of targeted interventions that consider the individual biological, including genetic data, environmental and behavioural characteristics, as well as the socio-cultural context. This protocol summarises the main features of a rapid scoping review to show the research landscape on biomarkers or a combination of biomarkers that may help to better identify subgroups of individuals with different risks of developing specific diseases in which specific preventive strategies could have an impact on clinical outcomes. This review is part of the “Personalised Prevention Roadmap for the future HEalThcare” (PROPHET) project, which seeks to highlight the gaps in current personalised preventive approaches, in order to develop a Strategic Research and Innovation Agenda for the European Union. Objective To systematically map and review the evidence of biomarkers that are available or under development in cancer, cardiovascular and neurodegenerative diseases that are or can be used for personalised prevention in the general population, in clinical or public health settings. Methods Three rapid scoping reviews are being conducted in parallel (February–June 2023), based on a common framework with some adjustments to suit each specific condition (cancer, cardiovascular or neurodegenerative diseases). Medline and Embase will be searched to identify publications between 2020 and 2023. To shorten the time frames, 10% of the papers will undergo screening by two reviewers and only English-language papers will be considered. The following information will be extracted by two reviewers from all the publications selected for inclusion: source type, citation details, country, inclusion/exclusion criteria (population, concept, context, type of evidence source), study methods, and key findings relevant to the review question/s. The selection criteria and the extraction sheet will be pre-tested. Relevant biomarkers for risk prediction and stratification will be recorded. Results will be presented graphically using an evidence map. Inclusion criteria Population: general adult populations or adults from specific pre-defined high-risk subgroups; concept: all studies focusing on molecular, cellular, physiological, or imaging biomarkers used for individualised primary or secondary prevention of the diseases of interest; context: clinical or public health settings. Systematic review registration https://doi.org/10.17605/OSF.IO/7JRWD (OSF registration DOI).

Keywords